sincalide

Trade name: kinevac

PeptideapprovedImaging agent

Approved

Jul 21, 1976

Sincalide is a synthetically-prepared C-terminal octapeptide of naturally occurring hormone cholecystokinin. Sincalide causes gallbladder contraction and stimulates secretion of pancreatic enzymes, and this property of the drug is used in diagnostic purposes. It is discussed that the drug acts by binding and stimulating the CCK-A receptor which is expressed in the target tissues. FDA approved sincalide under the name KINEVAC. — NCATS

Clinical trial activity

9 trials · 11 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 1, 1997 (NCT00004414)

Timeline

1970s

Jul 21, 1976
Bracco — Earliest FDA Approval
Jul 21, 1976
Bracco — NDA Secondary Org
Jul 21, 1976
Bracco — NDA Organization

2020s

Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Nov 22, 2022
Maia Pharms Inc — Marketing Organization
Nov 22, 2022
Maia Pharms Inc — NDA Secondary Org

Indications

Approved for

Studied for

Mechanism of action

Cholecystokinin A receptorAGONIST
Cholecystokinin A receptor agonist
- Cholecystokinin receptor type A (CCKAR) ↗
CholecystokininINHIBITOR
CCK inhibitor
- Cholecystokinin (CCK) ↗

Approval history

approvedPriority reviewJul 21, 1976

Chemistry & pharmacology

Loading structure…

SMILES

CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC4=CC=CC=C4)C(N)=O

Mol. weight: 1143.269 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Prescription Only
Multi-specific: No

Oral

Parenteral

Yes

Topical

Sources

Also known as

cck
cck-33
cck-8
cck-8
cck c-terminal octapeptide
cck c-terminal octapeptide
cck-pz
cck-pz
cholecystokinin
cholecystokinin
cholecystokinin
cholecystokinin
cholecystokinin
cholecystokinin 33
cholecystokinin-8
cholecystokinin c-terminal octapeptide
cholecystokinin c-terminal octapeptide
human cck-33
human cholecystokinin-33
kinevac
kinevac
kinevac
pancreozymin
pancreozymin
pancreozymin
pancreozymin
pancreozymin
pankreozymin
sincalide
sincalide
sincalide
sincalide
sincalide
sincalide
sincalide
sincalide
sincalide
sincalide
sq 19844
sq-19844
sq-19844
sq-19844
uropancreozymin

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT04567667	Phase 1	Sep 30, 2020	Bristol-Myers Squibb
NCT02748525	N/A	Apr 1, 2016	University of Texas at Houston
NCT02497313	N/A	Jul 1, 2015	University of Copenhagen
NCT02496221	Phase 4	Jun 1, 2015	GlaxoSmithKline
NCT02445508	N/A	May 1, 2015	Sanofi, University of Copenhagen
NCT01656057	N/A	Jul 1, 2012	University of Copenhagen
NCT00706381	N/A	Jun 19, 2008	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00685477	N/A	May 1, 2008	Johns Hopkins University, Memorial Health University Medical Center, Pennsylvania State University, Temple University
NCT00004414	N/A	Sep 1, 1997	University of Michigan

Showing 9 of 9 trials

Page 1 / 1

Organizations

Research & Development (11)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
University of Copenhagen	Academic/Hospital	3	3	1	2012
Bristol-Myers Squibb	For profit	1	1	1	2020
GlaxoSmithKline	For profit	1	1	1	2015
Johns Hopkins University	Academic/Hospital	1	0	1	2008
Memorial Health University Medical Center	Academic/Hospital	1	0	1	2008
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Government	1	1	1	2008
Pennsylvania State University	Academic/Hospital	1	0	1	2008
Sanofi	For profit	1	0	1	2015
Temple University	Academic/Hospital	1	1	1	2008
University of Michigan	Academic/Hospital	1	1	1	1997
University of Texas at Houston	Academic/Hospital	1	1	1	2016

11 organizations

Page 1 / 1

Marketing (4)

Organization	Org type	Relationship	Date
Bracco	For profit	NDA2	Jul 21, 1976
Bracco	For profit	NDA	Jul 21, 1976
Maia Pharms Inc	For profit	MKTG	Nov 22, 2022
Maia Pharms Inc	For profit	NDA2	Nov 22, 2022